BioCardia Announces One Thousand Case Safety Record for Morph® Deflectable Tip Guide Catheter

BioCardia’s Morph Vascular Access Business announces a one thousand case safety record for the Morph® deflectable tip guide catheter. The Morph® product family is based on state-of-the-art catheter technology that provides the ability to change the distal shape of the guide to navigate within the patient anatomy.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

South San Francisco, CA (PRWEB) October 8, 2006

BioCardia’s Morph Vascular Access Business announces a one thousand case safety record for the Morph® deflectable tip guide catheter. The Morph® product family is based on state-of-the-art catheter technology that provides the ability to change the distal shape of the guide to navigate within the patient anatomy. It is used by vascular surgeons, interventional radiologists, and interventional cardiologists in their practice of medicine.

The safety record of this advanced technology product is remarkable considering the difficult cases that are being performed, occasionally considered impossible to do without the Morph®. Improved control provided by the Morph often results in less procedural time, less manipulations within the anatomy, and less radiation exposure for both patients and physicians.

BioCardia CEO, Peter Altman, shares: “Our manufacturing, quality assurance, and development teams all hold patient safety as the number one priority. This safety milestone is to the credit of the individuals that make up these teams, and a sign of their teamwork. As we launch the next generation of Morphs, which BioCardia believes will define the future of vascular access, I am confident that all will work diligently to extend this safety record.”

Morph® catheters are based on micro machined nitinol shaft technology to provide control and precision. The Morph® product family has been used with success in: renal arteries, AAA graft implantations, iliac arteries, femoral arteries, celiac arteries, superior mesenteric arteries, lumbar artery coilings, coronary arteries, cardiac chambers, access to carotid arteries, and other applications. The Morph® is also the navigational backbone for BioCardia’s HelixTM biotherapeutic delivery platform for biointerventional cardiology.

About BioCardia

Formed in 1999, BioCardia, Inc. is a leader in the development of catheter systems which enable local delivery of devices and therapeutics to the heart and other organs. BioCardia currently is marketing the Morph® family of deflectable tip guide catheters.

For more information, contact: Investor Relations, BioCardia, Inc. 650-624-0900, Miranda Peto or see our website, http://www.biocardia.com.

###


Contact